The aim of this study was to compare the inhibitory effect of antibiotic combinations in vitro with efficacy in Galleria mellonella larvae in vivo to identify efficacious combinations that target Pseudomonas aeruginosa. P. aeruginosa NCTC 13437, a multidrug-resistant strain resistant to b-lactams and aminoglycosides, was used. Susceptibility to cefotaxime, piperacillin, meropenem, amikacin, levofloxacin and colistin alone, or in dual or triple combinations, was measured in vitro via a 24 h time-kill assay. In vitro results were then compared with the efficacy of the same dual or triple antibiotic combinations versus G. mellonella larvae infected with P. aeruginosa. G. mellonella haemolymph burden of P. aeruginosa was determined over 96 h post-infection and treatment with the most potent combination therapies. Many dual and triple combinations of antibiotics displayed synergistic inhibition of multidrug-resistant P. aeruginosa in vitro. There was little correlation between combinations that were synergistic in vitro and those that showed enhanced efficacy in vivo versus infected G. mellonella larvae. The most potent dual and triple combinations in vivo were cefotaxime plus piperacillin, and meropenem plus piperacillin and amikacin, respectively. Fewer combinations were found to offer enhanced therapeutic benefit in vivo compared with in vitro. The therapeutic benefit arising from treatment with antibiotic combinations in vivo correlated with reduced larval burden of P. aeruginosa. This study has identified antibiotic combinations that merit further investigation for their clinical potential and has demonstrated the utility of using G. mellonella to screen for novel antibiotic treatments that demonstrate efficacy in vivo.
INTRODUCTION
The majority of life-threatening infections caused by Pseudomonas aeruginosa are hospital-acquired due to increased colonization rates as a consequence of invasive procedures (e.g. catheterization and mechanical ventilation), greater likelihood of patients being immunocompromised, and broad-spectrum antimicrobial treatment having a detrimental effect on the normal flora (Lister et al., 2009) . Thus, P. aeruginosa is a frequent cause of nosocomial pneumonia, urinary tract infections, surgical site infections and bacteraemia particularly in the intensive care unit (Spencer, 1996; Lister et al., 2009) . Compounding the clinical problem of P. aeruginosa infection is the ease with which the organism acquires resistance to multiple antibiotics. The incidence of isolation of multidrug-resistant (MDR) strains (defined as resistant to three or more classes of antibiotics) is increasing. For example, a study of 37 000 P. aeruginosa isolates from intensive care units in the USA reported an increase in the proportion of MDR strains from 13 % to 21 % over the period 1997 -2002 (Livermore, 2002 . The rising incidence of MDR strains of P. aeruginosa complicates the therapy of infections that they cause because the immediate administration of an appropriate antibiotic therapy is a major factor determining a favourable outcome for the patient (Micek et al., 2005) . For example, infection with MDR P. aeruginosa was associated with increased mortality, hospital stay and requirement for surgical procedures (Aloush et al., 2006) .
In an effort to improve therapeutic outcome, many clinicians have attempted to treat MDR P. aeruginosa infections by empirical administration of dual combinations of antibiotics to increase the likelihood of achieving appropriate therapy. The rationale for this is that administration of two agents with different modes of action will increase the chance that the pathogen will be inhibited by at least one of the component drugs. For P. aeruginosa infections, the dual antibiotic combinations usually consist of an antipseudomonal b-lactam with an aminoglycoside or a fluoroquinolone (Tamma et al., 2012) . Other claimed advantages of combination treatments include synergistic inhibition and the potential to prevent the selection of resistant organisms. One disadvantage is that combination treatments that include an aminoglycoside can result in greater nephrotoxicity when compared with the constituent monotherapies (Tamma et al., 2012) .
Many studies have identified synergistic inhibition of P. aeruginosa by diverse dual antibiotic combinations in vitro (He et al., 2012; Samonis et al., 2012; Tamma et al., 2012; Vidaillac et al., 2012) . Crucially, however, studies showing clinical evidence of enhanced efficacy of apparently synergistic combination treatments over the constituent monotherapies are less definitive and have been reviewed by Tamma et al. (2012) . In fact, in some studies, the presence of in vitro synergy did not correlate with clinical outcome at all (Chandrasekar et al., 1987; Hilf et al., 1989) . The fact that in vitro studies cannot take into account the variable pharmacokinetics and pharmacodynamics of antibiotics, or the presence of an active immune response to infection in vivo, could explain the poor correlation between in vitro and in vivo outcomes.
Whether or not combination therapy provides real clinical benefit for treatment of P. aeruginosa infections remains controversial and data from a number of studies are conflicting. The topic is comprehensively reviewed by Tamma et al. (2012) . Clearly, definitive therapy with a single antibiotic is the ideal scenario. Evidence of any therapeutic benefit from definitive antibiotic combinations over definitive monotherapy is unlikely. However, available evidence of enhanced efficacy from empirical combination therapy over empirical monotherapy is not conclusive (Bowers et al., 2013; Vardakas et al., 2013) . The situation is further complicated by differences in measured therapeutic benefit between monotherapy or combination treatment of different P. aeruginosa infections (Tamma et al., 2012) . As a consequence of this, there have been calls for additional research and more definitive studies (Vardakas et al., 2013) .
Plainly, there is an urgent clinical need to identify novel treatments for MDR P. aeruginosa. It is unlikely that new anti-pseudomonal drugs will be developed in the near future. Thus, it is necessary to make optimal use of the antibiotics that are currently available. Novel combinations of antibiotics could still be a potential solution to the problem but require initial screening and assessment of efficacy in appropriate in vivo infection models rather than reliance on in vitro studies to provide the best chance of success in patients.
In a recent study conducted in the corresponding author's laboratory, the suitability of a Galleria mellonella larva infection model for the study of the efficacy and pharmacokinetics of a range of anti-pseudomonal antibiotics was proven (Hill et al., 2013) . Employing a characterized MDR strain of P. aeruginosa (NCTC 13437), the aim of this study was to compare the inhibitory effect of antibiotic combinations in vitro with their efficacy in the G. mellonella model in vivo to identify combinations that could provide realistic future therapeutic options for treating infections with this organism.
METHODS
P. aeruginosa bacteria and growth media. P. aeruginosa NCTC 13437 was obtained from the National Collection of Type Cultures (http://www.hpacultures.org.uk/collections/nctc.jsp) and was cultured overnight in Mueller-Hinton broth (MHB; Merck) at 37 uC with shaking to prepare inocula for antibiotic susceptibility testing in vitro and antibiotic efficacy testing in vivo. NCTC 13437 is MDR and possesses two b-lactamases: VEB-1 extended-spectrum b-lactamase and VIM-10 metallo-carbapenemase, that render the strain multiply resistant to carbapenems and other b-lactam antibiotics. NCTC 13437 is also resistant to quinolones and aminoglycosides by unknown mechanisms (Woodford et al., 2008) .
Antibiotics and G. mellonella larvae. All antibiotics [cefotaxime (CTX), piperacillin (PIP), meropenem (MER), amikacin (AMK), levofloxacin (LVX) and colistin (CST)] and Pseudomonas Isolation Agar (PIA) were purchased from Sigma-Aldrich. All stock solutions and substocks were made using sterile deionized water. G. mellonella larvae were purchased from Livefood UK.
Antibiotic susceptibility testing. This was performed exactly as previously described (Hill et al., 2013) . Briefly, the MIC of each antibiotic versus P. aeruginosa NCTC 13437 was determined in 96-well microplates (Greiner Bio-one) via doubling dilution of each antibiotic in MHB and subsequent inoculation with 1.0610 6 c.f.u. ml 21 of P. aeruginosa NCTC 13437. Microplates were incubated at 37 uC and the MIC was defined as the concentration present in the first optically clear well after 24 h. The experiment was performed in triplicate.
Time-kill assay of P. aeruginosa viability. Viability of P. aeruginosa was determined in 96-well microplates after exposure to antibiotics alone or in combination. Aliquots from antibiotic stock solutions were added to wells containing MHB, while sterile water was added to control wells. Wells were inoculated with 1.0610 6 c.f.u. of P. aeruginosa ml 21 and the plate was incubated at 37 uC for 24 h. Subsequently, the abundance of viable cells in each well was determined by serial dilution in MHB and plating on nutrient agar. Plates were incubated at 37 uC for 24 h to permit colonies to form. Each treatment was replicated in quadruplicate and a mean value calculated. Here, synergy was defined at 24 h as a ¢2-log 10 reduction in c.f.u. ml 21 by the combination treatment relative to the most effective single treatment, so long as the combination reduced the starting inoculum by ¢2-log 10 c.f.u. ml 21 (White et al., 1996) . The minimum c.f.u. ml 21 detectable in this assay was 200.
G. mellonella model of P. aeruginosa infection and determination of G. mellonella haemolymph burden. This was performed exactly as previously described (Hill et al., 2013) . Unless otherwise stated, groups of larvae were infected with an inoculum of 2.5610 3 c.f.u. ml 21 of P. aeruginosa NCTC 13437 cells. A single treatment of each dual or triple antibiotic combination was administered 2 h post-infection (p.i). For experiments involving multiple doses of single antibiotics, or dual and triple antibiotic combinations, the second dose was administered 5 h p.i and the third dose 8 h p.i. Each experiment used groups containing 15 larvae and experiments were repeated twice using larvae from different batches.
The data from these replicate experiments were pooled to give n530. Survival data were plotted using the Kaplan-Meier method and comparisons made between groups using the log rank test. In all comparisons to the negative control it was the uninfected control (rather than the unmanipulated control) that was used. In all tests P¡0.05 was considered significant and Holm's correction was always applied to account for multiple comparisons (Holm, 1979) .
For haemolymph burden, groups of 30 larvae were infected with 2.5610 3 or 2.56106 c.f.u. ml 21 of P. aeruginosa. As above, single antibiotics or dual and triple combinations were administered at either 2 h p.i. as a single dose or at 2, 5 and 8 h p.i. for multiple dosing. The larvae were incubated in Petri dishes at 37 uC. At 24 h intervals, five larvae were selected at random from each treatment group and tested for haemolymph burden. No discrimination was made between live or dead larvae. Thus, in cases where the tested treatment offered minimal therapeutic benefit to the population, the majority of larvae sampled would be dead. In contrast, if the treatment regimen was successful, the majority of larvae sampled would be live. Selected larvae were anaesthetized and surface disinfected by vortexing in ethanol. The ethanol was poured off and the larvae allowed to dry. Once dry, each larva was placed into a separate Eppendorf tube containing 300 ml of sterile PBS. A clean Argos pestle (Argos Technologies) was washed in ethanol, flamed and used to homogenize the larva and release the haemolymph. A further 300 ml of sterile PBS was then added to each tube and vortexed. Twenty microlitres of the larval homogenate was serially diluted in 180 ml of MHB in a 96-well microplate (Greiner Bio-one). This process was repeated for each of the five larvae sampled per treatment group every 24 h. The dilution series was plated on PIA plates and incubated at 37 uC for 24 h. Colonies were counted after 24 h and the data expressed as viable c.f.u. ml
21
. Using this method the detection limit was 100 c.f.u. ml 21 of larval homogenate.
RESULTS

Dual and triple combinations of antibiotics display synergistic inhibition of MDR P. aeruginosa in vitro
The MICs of the antibiotics employed in this study (CTX, PIP, MER, CST, LVX and AMK) versus P. aeruginosa NCTC 13437 are shown in Table 1 . These MIC values verify those already published for this strain and further confirm that the strain has an MDR phenotype with high MIC values for all the drugs tested compared with a drugsensitive strain (with the exception of colistin) (Woodford et al., 2008; Hill et al., 2013) . Subsequently, the inhibitory effect of a 24 h exposure to the individual drugs alone at MIC 0.5 and the 15 possible dual combinations of the six antibiotics tested at MIC 0.5 was measured (Table 2) . With the exception of CST, exposure to the MIC 0.5 of each antibiotic alone had no inhibitory effect on growth compared with the untreated control. Exposure to 1 mg l 21 of CST did result in .2 log 10 c.f.u. ml 21 reduction over 24 h but did not reduce the cell numbers below the level of the initial inoculum. Out of the 15 dual antibiotic combinations, 10 reduced cell numbers below the detectable limit of the assay (2.3 log 10 c.f.u. ml
21
) compared with the untreated control and could be classed as synergistic (White et al., 1996) . Notably, of the 10 synergistic dual combinations, eight had one component b-lactam antibiotic and one consisted of two b-lactams (MER and PIP). The remaining synergistic combination consisted of CST with LVX. These 10 synergistic dual combinations were then tested again at MIC 0.25 ; no significant inhibitory effects were detected for any of the combinations at these lower concentrations (data not shown).
The effect of a 24 h exposure to the 20 possible triple antibiotic combinations at MIC 0.25 on P. aeruginosa NCTC 13437 is shown in Table 3 . Only four out of 20 triple combinations showed synergistic inhibition and resulted in a reduction in cell numbers below the detectable limit of the assay (2.3 log 10 c.f.u. ml
) compared with the untreated control. All four of these synergistic triple combinations included two b-lactam antibiotics and three of the combinations also included the aminoglycoside AMK. At MIC 0.125 , no inhibition was detected compared with the untreated control (data not shown).
Dual and triple combinations of antibiotics show enhanced efficacy compared with constituent monotherapies versus MDR P. aeruginosa infection in vivo
The efficacy of all the antibiotic combinations was measured in vivo using G. mellonella larvae infected with P. aeruginosa NCTC 13437 (Table 4 ). This experiment also allowed for comparison of the merit of screening for novel treatments in vitro versus an actual infection in vivo.
For each antibiotic combination, a dose of each constituent antibiotic was selected that alone provided minimal therapeutic benefit to larvae infected with P. aeruginosa NCTC 13437 (Hill et al., 2013) . This approach to dosing allowed for easy detection of any enhanced efficacy that arose upon administration of antibiotic combinations. Of the 15 possible dual combination treatments, only three showed significantly enhanced 96 h survival of infected G. mellonella at the lowest inoculum tested (2.5610 3 c.f.u. ml
21
). The best of these was the combination of two b-lactams (CTX+PIP), followed by PIP+AMK and PIP+LVX. ). This eliminated eight of the triple combinations with the seven remaining still showing significantly enhanced survival. The optimal triple combination was MER+PIP+AMK followed by CTX+PIP+AMK. Notably, both of these combinations include two b-lactams with an aminoglycoside. A single dose of all of these combinations had no therapeutic benefit on larvae inoculated with a high number of bacteria (2.5610 6 c.f.u. ml
).
The therapeutic benefit arising from treatment with antibiotic combination treatments correlates with reduced larval burden of infecting MDR P. aeruginosa
The effect of the most potent antibiotic combination treatments identified above on the larval burden of P. aeruginosa was compared with the effect of their constituent mono-or dual therapies. The effect of the dual combination of CTX+PIP is shown in Fig. 1 . Notably, exposure of infected larvae to a single dose of 100 mg kg
CTX+70 mg kg 21 PIP resulted in significantly enhanced survival (P¡0.05) compared with monotherapy with either 100 mg kg 21 CTX or 100 mg kg 21 PIP (Fig. 1a) . Measurement of larval burden of P. aeruginosa showed that treatment with either 100 mg kg 21 CTX or 70 mg kg 21 PIP alone had no inhibitory effect as there was rapid proliferation of P. aeruginosa within the larvae over a period of 24 h (Fig. 1b) and the numbers of P. aeruginosa recovered were similar to those from infected larvae treated with PBS alone (Hill et al., 2013) . In contrast, a single dose of the combination of CTX+PIP prevented the rapid growth of P. aeruginosa over 24 h and resulted in a significant reduction in the number of viable bacteria present within the larvae over the entire 96 h duration of the experiment (Fig. 1b) .
The effect of treatment with the optimal triple combination of MER+PIP+AMK on larval burden of P. aeruginosa was also examined (Fig. 2) . A single dose of 2 mg kg 21 MER+70 mg kg 21 PIP+50 mg kg 21 AMK resulted in greater than 80 % survival of infected larvae compared with the PBS-treated control. Treatment with the triple combination also resulted in significantly greater survival than any of the possible constituent dual therapies (P¡0.05) (Fig. 2a) . Confirming the data in enhanced survival compared with the PBS-treated control and the other two constituent dual combinations of AMK+MER and PIP+MER. However, the therapeutic benefit obtained from the triple therapy was significantly greater (P¡0.05) than that provided by PIP+AMK.
The dual combinations of AMK+MER and PIP+MER offered no therapeutic benefit over 96 h and this was reflected in rapid proliferation of P. aeruginosa within the larvae during the first 24 h post-treatment ( Fig. 2b ; only data for AMK+MER are shown for clarity). Treatment with either the triple combination or the constituent double combination PIP+AMK resulted in significant reductions in the number of viable P. aeruginosa recovered from the larvae compared with treatment with either AMK+MER or PIP+MER (P¡0.05). Reflecting the optimal larval survival seen after treatment with the triple combination compared with the double combination of PIP+AMK, there was an indication that the median numbers of bacteria recovered at 72 and 96 h from the infected larvae treated with the triple combination were approximately 1 log 10 c.f.u. ml 21 less than larvae treated with PIP+AMK, although this difference was not found to be significant (P¢0.05) (Fig. 2b ).
Multiple dosing with the triple combination of MER+PIP+AMK is efficacious versus an infection with high numbers of MDR P. aeruginosa in vivo
The effect of multiple doses of the optimal triple combination (MER+PIP+AMK) on larvae infected with a high inoculum of MDR P. aeruginosa (2.5610 6 c.f.u. ml
21
) is shown in Fig. 3 . Firstly, three doses of either MER, PIP or AMK alone had no significant therapeutic benefit on infected larvae over 96 h compared with treatment with PBS alone (Fig. 3a) . Three doses of the constituent dual therapies of the triple combination (PIP+AMK, AMK+MER and PIP+MER) all resulted in significantly enhanced survival compared with infected larvae treated with PBS alone (P¡0.05). However, the therapeutic benefit conferred by three doses of the triple combination was significantly greater than any of the dual antibiotic combinations (P¡0.05) (Fig. 3b) . Supporting our previous observation (Table 4) , a single dose of the triple Antibiotic combinations versus P. aeruginosa in vivo combination did not result in enhanced survival of larvae infected with a high inoculum over the duration of the experiment (Fig. 3c) . Both two and three doses of the triple combination did confer significantly enhanced survival compared with PBS-treated larvae (P¡0.05) but optimal therapeutic benefit was conferred by three doses (Fig. 3c) . The ineffective single dose of the triple combination did not prevent rapid proliferation of P. aeruginosa within the larvae over the first 48 h of the experiment (Fig. 3d) . In contrast, both the two and three dose regimens of the triple combination prevented this proliferation; in both cases the median value of recovered bacteria was significantly reduced when compared with bacterial numbers recovered from larvae exposed to a single dose. Notably, despite the three dose treatment offering significantly enhanced survival of infected larvae compared with just two doses (Fig. 3c) , there was no significant difference in the number of P. aeruginosa recovered between the two treatment regimens (P¢0.05) (Fig. 3d) .
DISCUSSION
G. mellonella larvae were shown recently to represent a highly effective model to test the efficacy of antibiotic treatments for P.aeruginosa infections in vivo. The efficacy of a range of antibiotics on larvae infected with an antibiotic-sensitive isolate or an MDR strain closely correlated with the known drug susceptibilities of the two strains in vitro and in patients (Hill et al., 2013) . Hence, the G. mellonella larval model offers real advantages for screening the effectiveness of novel anti-pseudomonal treatments due to its rapidity, low cost and lack of ethical concerns in comparison to the use of mammals.
In the work reported here, G. mellonella was used to screen the efficacy of multiple antibiotic combinations in vivo 13437/CTX 100 mg kg -1 + PIP 70 mg kg -1 Fig. 1 . (a) Effect of treatment with CTX, PIP or a combination of PIP and CTX on survival of G. mellonella larvae infected with 2.5¾10 3 c.f.u. ml "1 P. aeruginosa NCTC 13437. A single dose of the antibiotic treatments was administered 2 h p.i. The uninfected group represents larvae sham-infected with sterile PBS and treated with sterile PBS. *, significantly enhanced survival compared with PBS treatment (P,0.05, log rank test with Holm correction for multiple comparisons); n530 (pooled from duplicate experiments). (b) Effect of a single dose of CTX, PIP or a combination of CTX and PIP on larval burden of P. aeruginosa NCTC 13437. Larvae were infected with 2.5¾10 3 c.f.u. ml "1 of bacteria. A single dose of each treatment was administered 2 h p.i. #, a significant difference in larval burden between groups treated with the combination of CTX and PIP compared with the groups treated with CTX or PIP alone; n55 (P,0.05, Mann-Whitney U test). The horizontal bar represents the median value of larval burden per group.
Antibiotic combinations versus P. aeruginosa in vivo versus P. aeruginosa infection and compared with the inhibitory effect of the same combinations in an in vitro 24 h kill assay. A number of dual and triple combinations of anti-pseudomonal antibiotics demonstrated synergistic inhibition of MDR P. aeruginosa in vitro. This finding is not new and confirms a plethora of data within the literature which has been reviewed by Tamma et al. (2012) . However, comparison of the efficacy of the same combinations in vivo using G. mellonella larvae infected with MDR P. aeruginosa revealed little correlation with the inhibitory effects measured in vitro. For example, the dual combination of CTX+PIP significantly enhanced survival (b) Effect of a single dose of the dual antibiotic combinations AMK+MER, PIP+AMK and the triple combination of PIP+AMK+MER on larval burden of P. aeruginosa NCTC 13437 (the data for the remaining dual combination of PIP+MER were similar to those shown for AMK+MER and are omitted for clarity). Larvae were infected with 2.5¾10 3 c.f.u. ml "1 of bacteria. A single dose of each treatment was administered 2 h p.i. # , a significant difference in larval burden between groups treated with the combination of AMK+MER (and PIP+MER) compared with the groups treated with PIP+AMK or PIP+AMK+MER; n55 (P,0.05, Mann-Whitney U test); there was no significant difference between PIP+AMK and PIP+AMK+MER. The horizontal bar represents the median value of larval burden per group.
in vivo but displayed no synergistic inhibition under the conditions of the in vitro assay. This supports previous studies that compared results generated in vitro with clinical studies in patients (see Introduction) and further calls into question the utility of conducting initial screening for effective antibiotic combinations in vitro. Of the three dual combinations that showed enhanced efficacy in vivo, two included the combination of a b-lactam with either an aminoglycoside or a fluoroquinolone; such antibiotic combinations have been shown in some studies to offer enhanced outcomes compared with monotherapy in patients suffering from Gram-negative infections (Bodey et al., 1985; Al-Hasan et al., 2009) . Therefore, by screening for efficacious antibiotic combination treatments in vivo using G. mellonella, available evidence suggests that the data generated are more likely to be predictive of efficacy in patients than in vitro assays.
The most potent dual and triple antibiotic combinations that were identified using the G. mellonella model consisted of CTX+PIP and MER+PIP+AMK, respectively. Notably, out of seven triple antibiotic combination treatments shown to provide enhanced therapeutic benefit in vivo, only two were shown to be synergistic in vitro. Importantly, these findings imply that if screening of novel antimicrobials or combinations of antibiotics is performed initially in vitro, then treatments that are shown to be ineffective under these conditions would be discarded despite still having the Effect of one (2 h p.i), two (2 and 5 h p.i) or three (2, 5 and 8h p.i) doses of the triple combination PIP+AMK+MER. *, treatment with one dose resulted in significantly greater survival than with PBS; # , treatment with two doses resulted in significantly greater survival than with one dose;~, treatment with three doses resulted in significantly greater survival than with two doses. In all cases, the uninfected group represents larvae sham-infected with sterile PBS and treated with sterile PBS; significance represents P,0.05 (log rank test with Holm correction for multiple comparisons); n530 (pooled from duplicate experiments). (d) Effect of one, two or three doses of the triple combination of PIP+AMK+MER on larval burden of P. aeruginosa NCTC 13437. Larvae were infected with 2.5¾10 6 c.f.u. ml "1 of bacteria. *, significant difference in larval burden between two or three dose treatments compared with one dose; n55 (P,0.05, Mann-Whitney U test). There was no significant difference in larval burden between two or three doses. The horizontal bar represents the median value of larval burden per group.
Antibiotic combinations versus P. aeruginosa in vivo potential to be effective in vivo. Similarly, as this study shows, a large number of antibiotic combinations were identified as being potently synergistic in vitro but offered no enhanced therapeutic benefit over monotherapies when tested in vivo. Thus, the case for utilizing the G. mellonella model for initial screening of the effectiveness of novel antimicrobials, or combinations of antibiotics, is convincing.
The demonstration that the combination of CTX+PIP offered enhanced therapy in vivo is notable. Furthermore, out of seven triple antibiotic combinations that displayed enhanced therapeutic benefit in vivo, one consisted of three, and four included at least two b-lactams. Most attempts to identify synergistic combinations of antibiotics combine drugs with different inhibitory modes of action, with the obvious rationale that the inhibition of multiple bacterial targets is likely to lead to additive or synergistic inhibition that would be more potent than hitting a single essential target. Consequently, assessing the effectiveness of combinations of b-lactams that purportedly inhibit the same molecular targets is not intuitive; thus it is unlikely that they would be included in any screens. Furthermore, even if combinations of b-lactams were screened in vitro, as this work has shown, most would not be identified as synergistic and subsequently would never be evaluated in vivo. The consequence of this is that there could be a range of effective antibiotic combinations yet to be identified that could have the potential for clinical application.
Evidence of the effectiveness of dual b-lactam antibiotic combinations providing synergistic inhibition of P. aeruginosa in vitro is extensive (Scribner et al., 1982; Dales et al., 2009) . Oie et al. (2003) identified that the dual combination of PIP and ceftazidime significantly inhibited two out of seven strains of MDR P. aeruginosa. In the same study, triple combinations of b-lactams, including PIP, MER and ceftazidime, or PIP, ceftazidime and aztreonam, had significant activity against three and five of the seven strains, respectively. Supporting our findings, the authors reported that the triple combination of MER, PIP and AMK (the most potent triple combination that was identified using the G. mellonella infection model) inhibited three out of the seven MDR P. aeruginosa strains tested in vitro.
Notably, there are few published studies on the efficacy of b-lactam combinations in vivo. One study compared the efficacy of cefoperazone with PIP, ceftazidime with PIP, and imipenem alone on febrile granulocytopenic patients and concluded that the dual antibiotic combinations were as effective as the monotherapy but offered no enhanced therapeutic benefit (Winston et al., 1991) .
In summary, using G. mellonella, we have presented evidence that a dual combination of CTX with PIP, and triple combinations of antibiotics that include at least two different b-lactams, result in enhanced therapeutic benefit compared with monotherapies versus MDR P. aeruginosa infection in vivo. Furthermore, this study has emphasized the inadequacy of screening for novel treatments in vitro and highlighted the potential for carrying out these screens in vivo using G. mellonella larvae. In future, we plan to assess the efficacy of the novel antibiotic combinations that were identified in G. mellonella in suitable mammalian models to further develop their potential for clinical application.
